Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Curent Deferred Tax Liability Curent Deferred Tax Liability Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Deferred Tax Assets Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Long-Term Deferred Tax Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Pension Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Harvard Bioscience (HBIO) Short-term Investments (2018 - 2024)

Harvard Bioscience (HBIO) has disclosed Short-term Investments for 2 consecutive years, with $34000.0 as the latest value for Q2 2024.

Quarterly Short-term Investments changed N/A to $34000.0 in Q2 2024 from the year-ago period, while the trailing twelve-month figure was $34000.0 through Jun 2024, changed N/A year-over-year, with the annual reading at -$170000.0 for FY2018, N/A changed from the prior year.
Short-term Investments for Q2 2024 was $34000.0 at Harvard Bioscience, up from -$170000.0 in the prior quarter.
The five-year high for Short-term Investments was $34000.0 in Q2 2024, with the low at $34000.0 in Q2 2024.